表紙
市場調查報告書

乾癬藥的全球市場:成長,趨勢,及預測(2019年∼2024年)

Psoriasis Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 391446
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
乾癬藥的全球市場:成長,趨勢,及預測(2019年∼2024年) Psoriasis Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 111 Pages
簡介

全球乾癬藥市場在2019年∼2024年間,預測將以9.3%的年複合成長率成長。

本報告提供全球乾癬藥市場的相關調查,市場機會和趨勢,成長及阻礙因素,各療法類型、作用機制、給藥途徑、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各療法類型
    • 生技藥品
    • 小分子全身藥
    • 局部療法
  • 各作用機制
    • TNFAlpha抑制劑
    • PDE4抑制劑
    • 白細胞介素抑制劑
    • 其他
  • 各給藥途徑
    • 口服
    • 非口服
    • 局部
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Johnson and Johnson (Janssen Biotech Inc.)
    • Celgene Corporation
    • 武田藥品工業株式會社
    • Stiefel Laboratories Inc.
    • Novartis AG
    • Amgen Inc.
    • Biogen Idec
    • AbbVie Inc.

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52557

The psoriasis drugs market is expected to register a CAGR of 9.3% during the forecast period. The primary factors that are responsible for the growth of this market include the increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs.

  • Among all these factors, one of the factors expected to have a major impact on the market growth is the increasing use of combination therapies. Research is continuing on the combination therapies approach. However, studies conducted suggest that it often eases psoriasis symptoms more effectively than either treatment by themselves. Biologics usually take a while to work.
  • Combining a biologic with a faster-acting systemic drug, such as cyclosporine, is usually much more effective and safer. With faster, longer-lasting results and fewer side effects, requiring lower doses, many doctors are prescribing combination therapies, which is, in turn, expected to drive the psoriasis drugs market. However, factors such as the side effects of existing medications may have a negative impact on the market growth.

Key Market Trends

Interleukin Inhibitors is Expected to Grow with a High CAGR in the Forecast Period

Interleukin inhibitors may witness the fastest growth during the forecast period, and the factors aiding these interleukin inhibitors are their improved safety and efficacy when compared to other psoriasis drugs, and their increased adoption among end users. Drugs, like Secukinumab and Ustekinumab, among others, are aiding the market growth as the usage of drugs is increasing each year. Another benefit of the IL-mode of therapy is for the patients who are intolerant or contraindicated to TNF-α inhibitor therapy.

North America Dominates the Market and is Expected to do so in the Forecast Period

North America currently dominates the market for psoriasis drugs, and it is expected to continue having a stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to the increasing prevalence of psoriasis, the presence of favorable government initiatives, the presence of developed healthcare infrastructure, high adoption of therapeutics, and the presence of key drug manufacturers. All these factors are expected to propel the market in the United States.

Competitive Landscape

The psoriasis drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The rising number of patients is attracting a few other players to enter the market, and a few smaller players are also expected to enter the market in the future, who may hold a substantial share. Companies are focused on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions for the development of novel products. Some of the major players of the market are Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services LLC), Novartis AG, and Amgen Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
    • 4.2.2 Increasing Use of Combination Therapies
    • 4.2.3 Increase in Psoriasis Research and Pipeline Drugs
  • 4.3 Market Restraints
    • 4.3.1 Adverse Side Effects of Existing Medications
    • 4.3.2 High Cost of Psoriasis Treatments
    • 4.3.3 Extensive Drug Development and Approval Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Treatment
    • 5.1.1 Biologic Drugs
    • 5.1.2 Small Molecule Systemic Drugs
    • 5.1.3 Tropical Therapies
  • 5.2 By Mechanism of Action
    • 5.2.1 TNF Alpha Inhibitors
      • 5.2.1.1 Etanercept
      • 5.2.1.2 Certolizumab Pegol
      • 5.2.1.3 Adalimumab
      • 5.2.1.4 Infiximab
      • 5.2.1.5 Golimumab
    • 5.2.2 PDE4 Inhibitors
      • 5.2.2.1 Apremilast
    • 5.2.3 Interleukin Inhibitors
      • 5.2.3.1 Secukinumab
      • 5.2.3.2 Ustekinumab
      • 5.2.3.3 Other Interleukin Inhibitors
    • 5.2.4 Other Mechanisms of Action
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
    • 5.3.3 Topical
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Pfizer Inc.
    • 6.1.3 Johnson and Johnson (Janssen Biotech Inc.)
    • 6.1.4 Celgene Corporation
    • 6.1.5 Takeda Pharmaceutical Company Limited
    • 6.1.6 Stiefel Laboratories Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Amgen Inc.
    • 6.1.9 Biogen Idec
    • 6.1.10 AbbVie Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS